Las Vegas Review-Journal

Justices appear skeptical of challenge to abortion medication

- By David G. Savage

WASHINGTON — U.S. Supreme Court justices sounded skeptical Tuesday about imposing new limits on the dispensing of abortion medication through pharmacies or by mail.

The justices, both conservati­ves and liberals, questioned whether a group of anti-abortion doctors have legal standing to challenge the dispensing rules set by the federal Food and Drug Administra­tion. That issue, not the safety of mifepristo­ne, dominated a two-hour hearing — likely a sign of what the justices thought about the case.

“The court should put an end to this case,” Solicitor Gen. Elizabeth Prelogar said on behalf of the Biden administra­tion Tuesday. A handful of doctors who oppose all abortions do not have the right to challenge the legal use of the medication by millions of women, she argued.

If the court were to uphold new restrictio­ns on dispensing the pills, the impact would be felt by women in California and other blue states where abortion is legal. Conversely, a ruling that the anti-abortion doctors in this case lack the legal standing to sue could forestall other challenges.

A decision by the court is expected later this session, most likely toward the end of June, as it wraps up.

Abortion pills, typically a combinatio­n of mifepristo­ne and a second drug, misoprosto­l, are now the most common method of ending a pregnancy in the U.S., used by 3 out of 5 abortion patients. Use of the drugs has grown significan­tly in the two years since the court’s Dobbs decision, which struck down the constituti­onal right to abortion.

During Tuesday’s hearing, only conservati­ve Justice Samuel Alito directly disputed arguments that the anti-abortion claim should be thrown out.

“Isn’t there anyone who could challenge this?” he asked.

Conservati­ve Justices Neil Gorsuch, Amy Coney Barrett and Brett Kavanaugh asked largely procedural questions.

Gorsuch questioned why a lawsuit brought in western Texas on behalf of a few anti-abortion doctors should lead to a nationwide injunction.

The case appears to be “a prime example of turning what could be a small lawsuit into a nationwide legislativ­e assembly,” Gorsuch said.

Barrett said the law already offered “conscience protection­s” to shield doctors who have moral objections to abortions from being required to perform them. She said she saw no evidence that those protection­s were not being honored.

Kavanaugh asked for clarificat­ion: “Under federal law, no doctors can be forced against their conscience­s to perform or assist in an abortion, correct?”

Yes, Prelogar replied.

In 2022, Gorsuch, Kavanaugh and Barrett cast crucial votes in the court’s 5-4 decision to strike down the longtime constituti­onal right to abortion.

The challenge to the legality of abortion medication posed a test for the court’s anti-abortion conservati­ves. The opinion in the Dobbs case said the regulation of abortion should be decided by states and elected officials, not judges.

During Tuesday’s arguments, Gorsuch and Barrett in particular questioned why judges in Texas had taken on the role of regulating abortion medication.

The court’s liberal members similarly questioned the basis for the case.

Justice Ketanji Brown Jackson said she saw “a significan­t mismatch” between what the anti-abortion doctors complained about and the remedy they were seeking.

“They’re saying, ‘Because we we object to having to participat­e in this procedure, we’re seeking an order preventing anyone from having access to these drugs at all,’ ” she said.

The court heard from three attorneys Tuesday, all women.

Jessica Ellsworth represente­d Danco, which makes and distribute­s mifepristo­ne. Agreeing with the solicitor general, she said the case demonstrat­es why judges should not “second-guess” the FDA on matters of drug safety.

She noted that U.S. District Judge Matthew Kacsmaryk in Amarillo, Texas, who issued an injunction against the FDA, “relied on one study that was an analysis of anonymous blog posts” and cited other studies that have “since been retracted for lack of scientific rigor and for misleading presentati­ons of data.”

Erin Hawley, a lawyer for the conservati­ve Christian group Alliance Defending Freedom, represente­d the anti-abortion doctors. She said the fact that some women will encounter side effects from the medication and seek treatment at emergency rooms means that some doctors who oppose abortion will be forced to choose between “helping a woman with a life-threatenin­g condition and violating their conscience.”

But she spent most of her time fending off questions that challenged her clients’ standing to sue.

The FDA approved the use of mifepristo­ne in 2000, saying it was safe and effective when taken in combinatio­n with misoprosto­l. In 2016 and 2021, the agency loosened restrictio­ns on how the pills may be prescribed.

The changes eliminated the requiremen­t for an in-person doctor visit before the pills could be prescribed. The FDA said that years of experience indicated that the in-person visits were not needed to ensure safety. That change opened the way for telemedici­ne prescripti­ons, which are now used by many women in states that ban abortions.

The pills cause cramping and some bleeding and can sometimes require a doctor’s interventi­on to complete the abortion. But the FDA says serious complicati­ons are “exceedingl­y rare,” noting that more than 5 million women in the U.S. have used the medication since 2000.

More than a dozen major medical groups, led by the American College of Obstetrici­ans & Gynecologi­sts and the

American Medical Associatio­n, said in friend-of-the court briefs that two decades of studies have shown the drugs are safe.

The frequency of their use has made the drugs a target for anti-abortion activists. Two years ago, shortly after the Dobbs ruling, a group of anti-abortion doctors filed the lawsuit in Amarillo.

They sought a court order that would overturn the FDA’S approval of the drugs. And they sought out a judge who would look favorably on their claim. Kacsmaryk, a Trump appointee who is the only federal judge based in Amarillo, “suspended” the FDA’S approval of mifepristo­ne and gave the government seven days to appeal his decision.

The U.S. 5th Circuit Court of Appeals in New Orleans partially reversed Kacsmaryk’s ruling, deciding that it was too late to reverse the FDA’S approval of the drug, but agreeing to set aside the regulation­s the agency has adopted since 2016.

Biden administra­tion lawyers appealed to the Supreme Court, and the justices voted to put the case on hold. Alito and fellow conservati­ve Justice Clarence Thomas dissented from that initial decision.

The tenor of the court’s response to Tuesday’s arguments in FDA vs. Alliance for Hippocrati­c Medicine suggested that a majority of the justices will vote to reverse the 5th Circuit, with Thomas and Alito dissenting again.

 ?? MAANSI SRIVASTAVA / THE NEW YORK TIMES ?? An abortion rights demonstrat­or faces off with an anti-abortion demonstrat­or Tuesday outside the Supreme Court building in Washington. During arguments Tuesday, the justices repeatedly questioned whether a group of anti-abortion doctors and organizati­ons had a right to challenge the Food and Drug Administra­tion’s approval of an abortion pill.
MAANSI SRIVASTAVA / THE NEW YORK TIMES An abortion rights demonstrat­or faces off with an anti-abortion demonstrat­or Tuesday outside the Supreme Court building in Washington. During arguments Tuesday, the justices repeatedly questioned whether a group of anti-abortion doctors and organizati­ons had a right to challenge the Food and Drug Administra­tion’s approval of an abortion pill.

Newspapers in English

Newspapers from United States